ECSP055865A - Perindopril - Google Patents

Perindopril

Info

Publication number
ECSP055865A
ECSP055865A EC2005005865A ECSP055865A ECSP055865A EC SP055865 A ECSP055865 A EC SP055865A EC 2005005865 A EC2005005865 A EC 2005005865A EC SP055865 A ECSP055865 A EC SP055865A EC SP055865 A ECSP055865 A EC SP055865A
Authority
EC
Ecuador
Prior art keywords
formula
deprotection
pharmaceutically acceptable
acceptable salt
free acid
Prior art date
Application number
EC2005005865A
Other languages
English (en)
Inventor
Rajendra Narayanrao Kankan
Charmaraj Ramachandra Rao
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of ECSP055865A publication Critical patent/ECSP055865A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Una sal farmacéuticamente aceptable de perindopril de fórmula (I) preparada a partir de un compuesto precursor protegido de fórmula (II) en donde R representa un grupo protector carboxilo, cuyo proceso comprende someter un compuesto de fórmula (II) a desprotección del grupo carboxílico COOR adherido al anillo heterocíclico de tal forma que produzca el correspondiente ácido libre, cuya desprotección se lleva a cabo en la presencia de una base que forma una sal farmacéuticamente aceptable con dicho ácido libre formado mediante dicha desprotección
EC2005005865A 2002-11-18 2005-06-17 Perindopril ECSP055865A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0226885A GB2395195A (en) 2002-11-18 2002-11-18 Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors

Publications (1)

Publication Number Publication Date
ECSP055865A true ECSP055865A (es) 2005-11-22

Family

ID=9948057

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005865A ECSP055865A (es) 2002-11-18 2005-06-17 Perindopril

Country Status (28)

Country Link
US (1) US7351840B2 (es)
EP (2) EP1688427B1 (es)
JP (2) JP5110770B2 (es)
KR (1) KR20050075429A (es)
CN (2) CN1966519A (es)
AT (2) ATE445632T1 (es)
AU (2) AU2003283588B2 (es)
BR (1) BR0315703A (es)
CA (1) CA2506587A1 (es)
DE (2) DE60329722D1 (es)
DK (1) DK1565485T3 (es)
EC (1) ECSP055865A (es)
ES (2) ES2279188T3 (es)
GB (1) GB2395195A (es)
GE (1) GEP20105036B (es)
HR (1) HRPK20050567B3 (es)
IL (1) IL168660A (es)
IS (1) IS7893A (es)
MA (1) MA27567A1 (es)
MX (1) MXPA05005333A (es)
NZ (1) NZ540360A (es)
PL (1) PL376931A1 (es)
PT (2) PT1565485E (es)
RU (1) RU2339645C2 (es)
SI (1) SI1565485T1 (es)
TN (1) TNSN05140A1 (es)
WO (1) WO2004046172A1 (es)
ZA (1) ZA200503979B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2395195A (en) * 2002-11-18 2004-05-19 Cipla Ltd Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors
CA2530550C (en) 2003-06-24 2017-04-04 Christoph Straessler New crystalline forms of perindopril erbumine
GB2413128A (en) * 2004-04-13 2005-10-19 Neopharma Ltd Process for the preparation of perindopril
SI21881A (sl) 2004-10-15 2006-04-30 Diagen, Smartno Pri Ljubljani, D.O.O. Nove kristalne oblike perindopril erbumin hidratov, postopek za njihovo pripravo in farmacevtske oblike, ki vsebujejo te spojine
WO2007017893A2 (en) * 2005-05-05 2007-02-15 Arch Pharmalabs Limited Preparation of novel crystalline form of perindopril erbumine monohydrate
WO2007017087A1 (en) * 2005-07-25 2007-02-15 Lek Pharmaceuticals D.D. Process for the preparation of crystalline perindopril
US20090099370A1 (en) * 2005-08-12 2009-04-16 Sandoz Ag Crystalline Form of Perindopril Erbumine
EP1943267B1 (en) * 2005-08-12 2011-03-16 LEK Pharmaceuticals d.d. A process for the preparation of perindopril erbumine
DE102005058166A1 (de) * 2005-12-05 2007-06-06 Hexal Ag Matrixkontrolliertes transdermales System mit Amin-Salzen der ACE-Hemmer-Dicarbonsäuren
SI22543A (sl) 2007-06-27 2008-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove soli perindoprila
CN101332191B (zh) * 2008-07-10 2013-01-09 沈阳药科大学 一种稳定的培哚普利叔丁胺盐片剂及其制备方法
SI23149A (sl) 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2433998C1 (ru) * 2010-03-16 2011-11-20 Закрытое акционерное общество "Активный Компонент" Способ получения периндоприла и его фармацевтически приемлемых солей
US8558023B2 (en) 2010-04-20 2013-10-15 Chiral Quest, Inc. Enantioselective process for cycloalkenyl β-substituted alanines
CN103110929A (zh) * 2012-12-10 2013-05-22 江苏开元医药化工有限公司 米屈肼和赖诺普利的药物组合物及其制备方法
CN105693817B (zh) * 2014-11-27 2020-06-05 西北大学 一类三肽化合物及其制备方法与应用
WO2016178591A2 (en) 2015-05-05 2016-11-10 Gene Predit, Sa Genetic markers and treatment of male obesity
CN111116709B (zh) * 2019-12-31 2022-06-24 北京鑫开元医药科技有限公司 一种培哚普利制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2503155A2 (fr) * 1980-10-02 1982-10-08 Science Union & Cie Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
FR2620709B1 (fr) * 1987-09-17 1990-09-07 Adir Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP4018854B2 (ja) 1999-10-28 2007-12-05 第一三共株式会社 抗悪性腫瘍薬
FR2807431B1 (fr) * 2000-04-06 2002-07-19 Adir Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
FR2811319B1 (fr) 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline beta du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2811320B1 (fr) 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline alpha du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2811318B1 (fr) * 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline gamma du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2838648B1 (fr) * 2002-04-18 2004-05-21 Servier Lab Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
GB2395195A (en) * 2002-11-18 2004-05-19 Cipla Ltd Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors
SI21881A (sl) 2004-10-15 2006-04-30 Diagen, Smartno Pri Ljubljani, D.O.O. Nove kristalne oblike perindopril erbumin hidratov, postopek za njihovo pripravo in farmacevtske oblike, ki vsebujejo te spojine

Also Published As

Publication number Publication date
BR0315703A (pt) 2005-10-25
EP1565485B1 (en) 2007-01-24
EP1688427A1 (en) 2006-08-09
ZA200503979B (en) 2006-11-29
GB0226885D0 (en) 2002-12-24
WO2004046172A1 (en) 2004-06-03
JP5110770B2 (ja) 2012-12-26
JP2006520320A (ja) 2006-09-07
JP2013006839A (ja) 2013-01-10
RU2339645C2 (ru) 2008-11-27
DE60329722D1 (de) 2009-11-26
KR20050075429A (ko) 2005-07-20
DK1565485T3 (da) 2007-03-12
CN1966519A (zh) 2007-05-23
ES2333153T3 (es) 2010-02-17
MXPA05005333A (es) 2005-08-16
HRPK20050567B3 (hr) 2007-08-31
EP1688427B1 (en) 2009-10-14
AU2003283588A1 (en) 2004-06-15
GEP20105036B (en) 2010-07-12
PT1688427E (pt) 2009-11-06
ES2279188T3 (es) 2007-08-16
EP1565485A1 (en) 2005-08-24
US7351840B2 (en) 2008-04-01
ATE445632T1 (de) 2009-10-15
AU2009202389A1 (en) 2009-07-09
DE60311516T2 (de) 2007-10-25
AU2009202389B2 (en) 2012-03-29
PT1565485E (pt) 2007-03-30
IS7893A (is) 2005-06-14
NZ540360A (en) 2007-12-21
CN1738830A (zh) 2006-02-22
TNSN05140A1 (en) 2007-05-14
PL376931A1 (pl) 2006-01-09
DE60311516D1 (en) 2007-03-15
CA2506587A1 (en) 2004-06-03
HRP20050567A2 (hr) 2005-12-31
IL168660A (en) 2010-04-15
SI1565485T1 (sl) 2007-08-31
AU2003283588B2 (en) 2009-07-16
MA27567A1 (fr) 2005-10-03
ATE352555T1 (de) 2007-02-15
CN100371345C (zh) 2008-02-27
US20060063941A1 (en) 2006-03-23
RU2005119162A (ru) 2006-01-20
GB2395195A (en) 2004-05-19

Similar Documents

Publication Publication Date Title
TNSN05140A1 (en) Perindopril
PE20020707A1 (es) Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c
SE0103046L (sv) Kristallin bas av citalopram
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
PE20040636A1 (es) Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina
AR051778A2 (es) Derivados del acido dimetilaminocrotonico y procesos para supreparacion
AR035728A1 (es) Proceso perfeccionado para la sintesis de carbapenem
EA200800924A1 (ru) Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера
CL2009000089A1 (es) Procesos de preparacion de un derivado del acido y-amino-o-bifenil-x-metil-pentanoico;compuestos intermediarios y su proceso de preparacion; uso de los compuestos en la sintesis de compuestos inhibidores de nep, utiles en enfermedades cardiovasculares, tales como hipertension, insuficiencia cardiaca congestiva, entre otras.
BR0014526A (pt) Compostos cìclicos de seis elementos contendo nitrogênio aromático
AR042206A1 (es) Acidos fenilaceticos y derivados
EA200400129A1 (ru) Способ получения периндоприла, его аналогов и солей с использованием 2,5-диоксооксазолидиновых промежуточных соединений
EA200000804A1 (ru) Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина
AR038624A1 (es) Un procedimiento para preparar un derivado de fenilalanina e intermediarios del mismo
ECSP045234A (es) PROCEDIMIENTO PARA LA FABRICACION DE DERIVADOS DE ACIDO MEVALONICO INHIBIDORES DE ß-HIDROXI-ß-METILGLUTARILO-CO-ENZIMA-A REDUCTASA
NO20024241L (no) FremgangsmÕte for fremstilling av citalopram
DE60331586D1 (de) Festphase fluorierung von uracil
CO5611125A2 (es) Derivados de azetidina como antagonistas del receptor ccr-3
HRP20040781B1 (en) Process for the preparation of high purity perindopril and intermediates useful in the synthesis
CO5210865A1 (es) Proceso para la produccion de los acidos 2-fenilamino-5-aceticos
DE60316436D1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
BRPI0409095A (pt) processos de sìntese do ácido (2s)-indolina-2-carboxìlico, e aplicação para a sìntese do perindopril
EA200200463A1 (ru) Способ стереоселективного синтеза циклических аминокислот
BRPI0416746A (pt) processo de sìntese do perindopril e de seus sais farmaceuticamente aceitáveis
EE04345B1 (et) Simvastatiini ja selle derivaatide valmistamise protsess